ACTIMMUNE

Horizon Pharma PLC (NASDAQ: HZNP), a biopharmaceutical company that focuses on unmet medical needs, announced Thursday topline results from a Phase 3 study called STEADFAST. The trial evaluated Horizon's ACTIMMUNE therapy for the treatment of of Friedreich's ataxia, a rare inherited...